Please assess the completion status of the following clinical trial:

Trial Title: Study to Investigate Safety, Efficacy of an Anti-IFNγ mAb in Children With Primary Haemophagocytic Lymphohistiocytosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Gender: male and female~* Age: up to and including 18 years at diagnosis of Haemophagocytic Lymphohistiocytosis~* Primary HLH patients~* Patient (if ≥ 18 years old), or patient's legal representative(s) must have signed informed consent~Exclusion Criteria:~* Diagnosis of secondary Haemophagocytic Lymphohistiocytosis consequent to a proven rheumatic or neoplastic disease.~* Body weight \< 3 kg.~* Patients treated with biologics within a specific timeframe~* Active Mycobacteria, Histoplasma Capsulatum, Shigella, Salmonella, Campylobacter and Leishmania infections.~* Presence of malignancy.~* Concomitant disease or malformation severely affecting the cardiovascular, pulmonary, liver or renal function

- Gender: ALL
- Minimum Age: None
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- NI-0501 (Type: EXPERIMENTAL): NI-0501 administered by IV infusion at a starting dose of 1 mg/kg.

Based on this trial design, predict the completion outcome and termination type (if applicable).